欧洲泌尿外科学会指南:肌层浸润性和转移性膀胱癌2025指南摘要
本文为2025年欧洲泌尿外科学会(EAU)肌层浸润性和转移性膀胱癌(MMIBC)指南摘要,通过结构化文献评估(检索Medline、EMBASE和Cochrane图书馆)形成推荐,涵盖诊断、治疗和随访。2025版关键更新包括基于FGFR3突变选择埃达替尼、围手术期放疗与女性性器官保留技术更新、基于SWOG试验的根治性膀胱切除术与淋巴结清扫范围推荐、医院手术量推荐、三联治疗后挽救性膀胱切除术推荐、辅助纳武利尤单抗推荐更新、HER2过表达时德曲妥珠单抗推荐,以及删除戈沙妥珠单抗推荐。
要点
- 强调多学科团队诊疗和与患者共同决策的重要性。
- 新增基于易感FGFR3突变选择不可切除或转移性尿路上皮癌患者使用埃达替尼的推荐。
- 更新围手术期放疗、女性性器官保留技术、根治性膀胱切除术及淋巴结清扫范围等推荐。
核心结论
- 2025年EAU指南为MMIBC患者的危险因素、诊断、分类、治疗和随访提供见解,旨在有效整合进入临床实践。
研究设计与样本
- 通过结构化文献评估检索Medline、EMBASE和Cochrane图书馆,由指南小组制定推荐,推荐强度基于利弊平衡、证据质量及患者价值观和偏好确定。
主要发现
- 2025年MIBC指南关键变化包括:新增基于易感FGFR3突变选择不可切除或转移性尿路上皮癌患者使用埃达替尼的推荐。
- 对女性术前和术后放疗及性器官保留技术的推荐进行了重大调整和更新。
- 基于SWOG试验结果新增关于根治性膀胱切除术和淋巴结清扫范围的推荐,并新增医院手术量相关推荐。
- 新增三联治疗后挽救性膀胱切除术推荐,以及所有适合三联膀胱保留治疗的患者在多学科团队中通过共同决策管理的推荐。
- 对不适合或拒绝辅助顺铂化疗的pT3/4和/或pN+患者辅助纳武利尤单抗推荐进行重大调整和更新;新增HER2过表达时德曲妥珠单抗的转移性疾病推荐;因制造商撤回美国食品药品监督管理局批准而删除戈沙妥珠单抗推荐;更新MIBC随访并全面更新管理算法。
关键数值与推荐
- 新增推荐:使用易感FGFR3突变选择不可切除或转移性尿路上皮癌患者接受埃达替尼治疗。
- 基于SWOG试验结果新增根治性膀胱切除术和淋巴结清扫范围的推荐。
- 新增三联治疗后挽救性膀胱切除术推荐,以及适合三联膀胱保留治疗患者在多学科团队中通过共同决策管理的推荐。
- 对不适合或拒绝辅助顺铂化疗的pT3/4和/或pN+患者,对辅助纳武利尤单抗推荐进行重大调整和更新。
- 新增HER2过表达时转移性疾病使用德曲妥珠单抗的推荐;因制造商撤回美国食品药品监督管理局批准而删除戈沙妥珠单抗推荐。
临床怎么用
- 指南强调对MMIBC患者进行彻底诊断、治疗和随访的重要性。
- 指南强调MMIBC患者治疗中多学科方法和与患者共同决策的重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: This publication represents a summary of the updated 2025 European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). The aim is to provide practical recommendations on the clinical management of MMIBC with a focus on diagnosis, treatment, and follow-up. METHODS: For the 2025 guidelines, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: The key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with MMIBC. The guidelines stress the importance of a multidisciplinary approach to the treatment of MMIBC patients and the importance of shared decision-making with patients. The key changes in the 2025 muscle-invasive bladder cancer (MIBC) guidelines include the following: a new recommendation for the use of susceptible FGFR3 alterations to select patients with unresectable or metastatic urothelial carcinoma for treatment with erdafitinib; significant adaption and update of the recommendations for pre- and postoperative radiotherapy and sexual organ-preserving techniques in women; new recommendation related to radical cystectomy and extent of lymph node dissection based on the results of the SWOG trial; recommendation related to hospital volume; new recommendations for salvage cystectomy after trimodality therapy and for the management of all patients who are candidates for trimodality bladder-preserving treatment in a multidisciplinary team setting using a shared decision-making process; significant adaption and update to the recommendation for adjuvant nivolumab in selected patients with pT3/4 and/or pN+ disease not eligible for, or who declined, adjuvant cisplatin-based chemotherapy; and addition of a new recommendation for metastatic disease regarding the antibody-drug conjugate trastuzumab deruxtecan in case of HER2 overexpression; in addition, removal of the recommendations on sacituzumab govitecan as the manufacturer has withdrawn the US Food and Drug Administration approval for this product; update of the follow-up of MIBC; and full update of the management algorithms of MIBC. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2025 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, treatment, and follow-up of MIBC patients and is designed for effective integration into clinical practice.
引用
- van der Heijden AG, Bruins HM, Carrion A, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. Eur Urol. 2025. PMID: 40118736. doi:10.1016/j.eururo.2025.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。